News

FDA Approves Avastin for Platinum-Sensitive Recurrent Ovari...

FDA Approves Avastin for Platinum-Sensitive Recurrent Ovarian Cancer

December 9, 2016

(Dec. 9, 2016) This week Genentech announced that the US Food and Drug Administration has expanded approval for bevacizumab (Avastin) to include patients with platinum-sensitive, recurrent disease, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine chemotherapy, followed by Avastin alone. The approval is based on two large Phase III … Continued

Research

Managing Recurrence: What You Need to Know (Webinar Available)

Managing Recurrence: What You Need to Know (Webinar Available)

November 30, 2016

Recurrence is in the back of every ovarian cancer survivor’s mind. In this presentation, originally broadcast on November 28, 2016, Dr. Sarah Adams provided an overview of strategies for managing recurrent ovarian cancer, discussing the goals of treatment during recurrence, typical courses of treatment, and advice on how to approach making decisions about treatment during … Continued

Information

OCRFA Welcomes New Scientific Advisory Committee Members

OCRFA Welcomes New Scientific Advisory Committee Members

November 10, 2016

OCRFA recently welcomed four new members to the Scientific Advisory Committee (SAC), our world-class group of leaders in the ovarian cancer field who review and approve all OCRFA research grants. Ronald Alvarez, MD, MBA, of Vanderbilt University Medical Center, Deborah Armstrong, MD, of Johns Hopkins School of Medicine, Robert Coleman, MD, of M.D. Anderson Cancer … Continued

OCRA News

OCRFA Funded Research Identifies Protein Group Responsible ...

OCRFA Funded Research Identifies Protein Group Responsible For Senescence’s Negative Side Effects

November 3, 2016

(Nov. 3, 2016) Senescence is the state when normal, healthy cells no longer have the ability to divide, which can occur during chemotherapy or when cancer genes within that cell are activated. Senescence can be very useful, for example, when one wants to stop cancer cells from rapidly dividing, but there can be negative side … Continued

OCRA News

OCRFA Funded Study Explores New Role of Estrogen in Anti-Tu...

OCRFA Funded Study Explores New Role of Estrogen in Anti-Tumor Immunity

October 31, 2016

(October 31, 2016) Estrogen signaling is a known factor in how certain estrogen receptive (ER positive) tumors grow in breast and ovarian cancers. That signaling, which can promote malignant tumor growth, can sometimes be effectively treated with anti-estrogen therapy, such as tamoxifen. What is less understood, and currently being studied at the Wistar Institute, is … Continued

OCRA News

OCRFA Launches New Website

OCRFA Launches New Website

October 14, 2016

We’re excited to announce that OCRFA’s new and refreshed website is live. The new site is reflective of the merger of Ovarian Cancer Research Fund and the Ovarian Cancer National Alliance to become Ovarian Cancer Research Alliance or OCRFA, the largest and oldest non-profit organization dedicated to advancing cancer research, while supporting women and their … Continued

OCRA News

OCRFA applauds FDA’s statement on ovarian cancer screening ...

OCRFA applauds FDA’s statement on ovarian cancer screening test

October 13, 2016

On September 7th, the FDA issued an important safety communication about tests marketed as ovarian cancer screening tests, including the ROCA Test developed by Abcodia Incorporated. The FDA states, “despite extensive research and published studies, there are currently no screening tests for ovarian cancer that are sensitive enough to reliably screen for ovarian cancer without a … Continued

Advocacy

Risk-reducing Oophorectomy is Risky, Study Shows

Risk-reducing Oophorectomy is Risky, Study Shows

October 12, 2016

A Mayo Clinic research team has found evidence suggesting that premenopausal women who are not at high risk of ovarian cancer should not have their ovaries removed for the purpose of cancer prevention. Premature removal of the ovaries can lead to a higher risk of anywhere from 8 to 18 chronic health conditions including coronary … Continued

Research

Niraparib Significantly Improves Outcome of Ovarian Cancer ...

Niraparib Significantly Improves Outcome of Ovarian Cancer Patients

October 11, 2016

(October 11, 2016) According to research published this month in the New England Journal of Medicine, the PARP inhibitor niraparib improves progression free survival in recurrent, platinum-sensitive women both with and without germline BRCA mutations. In a randomized, double-blind, phase III trial of over 550 women both with and without germline BRCA mutations, researchers found … Continued

Research

#30DaysofTeal: Day 30

#30DaysofTeal: Day 30

October 5, 2016

Our #30DaysofTeal campaign spotlighted education and awareness facts about ovarian cancer. You, this amazing and strong community helped us educate 2.5 MILLION people about ovarian cancer throughout September. But awareness doesn’t stop today. Follow us year-round for the latest updates on research, advocacy and news about ovarian cancer. Today’s #30DaysofTeal sponsored by AstraZeneca US Community … Continued

Community

#30DaysofTeal: Day 29

#30DaysofTeal: Day 29

October 5, 2016

Over 30,000 women and caregivers have found friends, support, strength and community on OCRFA’s Ovarian Cancer Community on Inspire.  If you haven’t signed up yet, visit today to meet your online community. This #30DaysofTeal proudly sponsored by Astrazeneca

Community

#30DaysofTeal: Day 28

#30DaysofTeal: Day 28

October 5, 2016

Have you seen our State Report Card, “50 States of Teal”? “50 States of Teal” revealed an overall trend: where a woman lives has a significant impact on her healthcare. Visit www.50statesofteal.org to read the report and see how your state scored. Plus find ways to take action at home. A woman’s healthcare shouldn’t be … Continued

Community